Richard Trollope

Richard Trollope has a diverse work experience spanning over several years. Richard started their career as a Medical/Hospital Representative at Wyeth Pharmaceuticals in 1996. In 2000, they joined Yamanouchi as a Key Account Manager and later became a Training Manager. Richard then moved to Astellas Pharma, where they served as a Regional Business Manager before being promoted to UK Brand Manager for Flomaxtra XL and Transplantation.

In 2008, Trollope joined Mundipharma International as a European Product Manager for Oncology, and later became the European Marketing Manager. Richard then moved to Napp Pharmaceuticals Holdings Limited in 2013, where they initially worked as an Oncology Business Unit Manager and later became the Director of the Specialty Care Business Unit.

In 2017, Trollope returned to Mundipharma International Limited, where they held various roles including Head of Biosimilars, Commercial Head of Oncology, and Commercial Director for Tinostamustine. Richard then worked at Clovis Oncology as the Commercial Director for the UKINORD region before joining Stemline Therapeutics in 2023 as the Commercial Director for the UK, Ireland, and Nordics.

Throughout their career, Trollope has acquired extensive experience in the pharmaceutical industry, particularly in oncology and commercial leadership roles.

Richard Trollope attended Cranbrook School from 1987 to 1991. Following their secondary education, they enrolled at the University of Exeter for the period of 1991 to 1994. At the university, they pursued a degree in Biological Sciences and graduated with a 2i classification.